Effect of linezolid in ventilator-associated pneumonia caused by MRSA

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 2, 2009, Pages 183-188

  Ellis, Michael W ^a  

^a Uniformed Services University of the Health Sciences   (United States)

Author keywords

Linezolid; Methicillin resistant; MRSA; Staphylococcus aureus; Vancomycin; Ventilator associated pneumonia

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; THROMBOCYTOPENIA; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 69449095893     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.7.2.183     Document Type: Article

References (47)

1. Wunderink RG, Mendelson MH, Somero MS et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 134, 1200-1207 (2008).
2. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171, 388-416 (2005).
3. Kollef MH, Morrow LE, Niederman MS et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 129, 1210-1218 (2006).
4. Weber DJ, Rutala WA, Sickbert-Bennett EE, Samsa GP, Brown V, Niederman MS. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect. Control Hosp. Epidemiol. 28, 825-831 (2007).
5. Wunderink RG, Cammarata SK, Oliphant TH et al. Continuation of a randomized, double-blind multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25, 980-992 (2003).
6. Rubinstein E, Cammarata SK, Oliphant TH et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32, 402-412 (2001).
7. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124, 1789-1797 (2003).
8. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 30, 388-394 (2004).
9. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant S. aureus infections in the United States. JAMA 298, 1763-1771 (2007).
10. Stevens DL. The role of vancomycin in the treatment paradigm. Clin. Infect. Dis. 42, S51-S57 (2006).
11. Boselli E, Breilh D, Rimmele T et al. Pharmacokinetic and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit. Care Med. 33, 1529-1533 (2005).
12. Gerbeaux P, Ledoray V, Boussuges A, Molenat F, Jean P, Sainty JM. Diagnosis of nosocomial pneumonia in mechanically ventilated patients: repeatability of the lavage. Am. J. Respir. Crit. Care Med. 157, 76-80 (1998).
13. Shorr AF, Combes A, Kollef M, Chastre J. Methicillin-resistant S. aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit. Care Med. 34, 700-706 (2006).
14. Baughman RP, Kerr MA. Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosis. J. Intens. Care Med. 18, 269-274 (2003).
15. Reyes N, Skinner R, Kaniga K et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 4344-4346 (2005).
16. Hegde S, Reyes N, Skinner R, Difuntorum S. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 61, 169-172 (2008).
17. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton - Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 128, 2732-2738 (2005).
18. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 195, 202-211 (2007).
19. Bernardo K, Pakulat N, Fleer S et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob. Agents Chemother. 48, 546-555 (2004).
20. Francis JS, Doherty MC, Lopatin U et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton - Valentine leukocidin gene. Clin. Infect. Dis. 40, 100-107 (2005).
21. Labandeira-Rey M F, Couzon S, Boisset EL et al. Staphylococcus aureus Panton Valentine leukocidin causes necrotizing pneumonia. Science 313, 1130-1133 (2007).
22. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 44, 1536-1542 (2007).
23. Deresinksi S. Counterpoint: vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence. Clin. Infect. Dis. 44, 1543-1548 (2007).
24. Moise-Broder PA, Forrest A, Birmingham MC, Scentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43, 925-942 (2004).
25. Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia. Chest 130, 947-955 (2006).
26. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42, S35-S39 (2006).
27. Lamer C, De Beco V, Soler P et al. Analysis of vancomycin into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother. 37, 281-286 (1993).
28. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC bactericidal activity to efficacy of vancomycin treatment of methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 42, 2398-2402 (2004).
29. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch. Intern. Med. 166, 2138-2144 (2006).
30. Tenover FC, Moellering RC, The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. J. Infect. Dis. 44, 1208-1215 (2007).
31. Chiang F, Climo M. Efficacy of linezolid alone or in combination with vancomycin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 3002-3004 (2003).
32. Grohs P, Kitzis M, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 418-420 (2003).
33. Jacqueline C, Caillon J, Le Mabecque V et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time - kill curve methods. J. Antimicrob. Chemother. 51, 857-864 (2003).
34. Pea F, Viale P. The antimicrobial puzzle: could pharmacokinetic - pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin. Infect. Dis. 42, 1764-1771 (2006).
35. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115, 674-680 (1991).
36. Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin. Microbiol. Infect. 12, 92-95 (2006).
37. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An updated from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
38. Lodise TP, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo Simulation. Antimicrob. Agents Chemother. 52, 2300-2304 (2008).
39. Shorr AF, Niederman M, Kollef MH et al. Telavancin: a novel agent for ventilator-associated pneumonia due to Staphylococcus aureus. Chest 134, S11002 (2008).
40. Kola A, Gastmeier P. Efficacy of oral chlorhexidine in preventing lower respiratory tract infections. Meta-analysis of randomized controlled trials. J. Hosp. Infect. 66, 207-216 (2007).
41. de Smet AM, Kluytmans JA, Cooper BS et al. Decontamination of the digestive tract and oropharynx in ICU patients. N. Engl. J. Med. 360, 20-31 (2009).
42. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogue S, Ferrer M. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 354, 1851-1858 (1999).
43. Dezfulian C, Shojania K, Collard HR, Kim HM, Matthay MA, Saint S. Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis. Am. J. Med. 118, 11-18 (2005).
44. Kollef MH, Afessa B, Anzueto A et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 300, 805-813 (2008).
45. Robicek A, Beaumont JL, Paule SM et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann. Intern. Med. 148, 409-418 (2008).
46. Popovich KJ, Winstein RA, Hota B. Are community-associated methicillin resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin. Infect. Dis. 46, 787-794 (2008).
47. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290, 2976-2984 (2003).